144 related articles for article (PubMed ID: 36796681)
41. Alternate Anti-Leprosy Regimen for Multidrug Therapy Refractory Leprosy: A Retrospective Study from a Tertiary Care Center in North India.
Narang T; Bishnoi A; Dogra S; Saikia UN; Kavita
Am J Trop Med Hyg; 2019 Jan; 100(1):24-30. PubMed ID: 30298809
[TBL] [Abstract][Full Text] [Related]
42. Adverse reactions induced by MDT/WHO (Rifampicin+Clofazimine+Dapsone) and ROM (Rifampicin+Ofloxacin+Minocycline) regimens used in the treatment of leprosy: a cohort study in a National Reference Center in Brazil.
Celestino IC; Antunes DE; Santos DF; Gimenes VL; de Souza FM; Goulart IMB
Front Pharmacol; 2024; 15():1346169. PubMed ID: 38515839
[No Abstract] [Full Text] [Related]
43. Relapse with multibacillary leprosy caused by rifampicin sensitive organisms following paucibacillary multidrug therapy.
Soares DJ; Neupane K; Britton WJ
Lepr Rev; 1995 Sep; 66(3):210-3. PubMed ID: 7500815
[TBL] [Abstract][Full Text] [Related]
44. Adverse effects of multi-drug therapy in leprosy, a two years' experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur).
Singh H; Nel B; Dey V; Tiwari P; Dulhani N
Lepr Rev; 2011 Mar; 82(1):17-24. PubMed ID: 21644468
[TBL] [Abstract][Full Text] [Related]
45. Minocycline is effective and cosmetically preferred to clofazimine by leprosy patients in New York.
Levis WR; Spencer TI; Ladizinski B
J Drugs Dermatol; 2010 Aug; 9(8):906. PubMed ID: 20684139
[No Abstract] [Full Text] [Related]
46. Relapse study in smear positive multibacillary (MB) leprosy after 1 year WHO-multi-drug therapy (MDT) in Cebu, Philippines.
Maghanoy A; Mallari I; Balagon M; Saunderson P
Lepr Rev; 2011 Mar; 82(1):65-9. PubMed ID: 21644473
[TBL] [Abstract][Full Text] [Related]
47. Fixed-duration therapy (FDT) in multibacillary leprosy; efficacy and complications.
Vijayakumaran P; Jesudasan K; Manimozhi N
Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):123-7. PubMed ID: 8690969
[TBL] [Abstract][Full Text] [Related]
48. [Guideline for the treatment of Hansen's disease in Japan].
Goto M; Ishida Y; Gidoh M; Nagao E; Namisato M; Ishii N; Ozaki M;
Nihon Hansenbyo Gakkai Zasshi; 2000 Nov; 69(3):157-77. PubMed ID: 11187723
[TBL] [Abstract][Full Text] [Related]
49. Dapsone hypersensitivity syndrome in an adolescent during treatment during of leprosy.
Bucaretchi F; Vicente DC; Pereira RM; Tresoldi AT
Rev Inst Med Trop Sao Paulo; 2004; 46(6):331-4. PubMed ID: 15654479
[TBL] [Abstract][Full Text] [Related]
50. Six years' follow-up of multibacillary leprosy patients treated with uniform multi-drug therapy in China.
Shen J; Yan L; Yu M; Li J; Yu X; Zhang G
Int J Dermatol; 2015 Mar; 54(3):315-8. PubMed ID: 25265933
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of anti-bacterial activity of Rifapentine, Clarithromycin, Minocycline, Moxifloxacin, Ofloxacin and their combinations in Murine Model of Rifampicin Resistant Leprosy.
Joseph P; Ponnaiya J; Das M; Chaitanya VS; Arumugam S; Ebenezer M
Indian J Lepr; 2016; 88(3):147-58. PubMed ID: 30207440
[TBL] [Abstract][Full Text] [Related]
52. Longitudinal ocular survey of 202 Filipino patients with multi-bacillary (MB) leprosy treated with 2 year WHO-multiple drug therapy.
Ravanes JM; Cellona RV; Balagon M; Abalos RM; Walsh GP; Walsh DS
Southeast Asian J Trop Med Public Health; 2011 Mar; 42(2):323-30. PubMed ID: 21710853
[TBL] [Abstract][Full Text] [Related]
53. Aplastic anaemia associated with multidrug therapy (dapsone, rifampicin and clofazimine) in a patient with lepromatous leprosy.
Goulart IM; Reis AC; De Rezende TM; Borges AS; Ferreira MS; Nishioka SA
Lepr Rev; 2005 Jun; 76(2):167-9. PubMed ID: 16038251
[No Abstract] [Full Text] [Related]
54. Influence of acetylator phenotype on the haematological and biochemical effects associated with dapsone in leprosy patients.
Queiroz RH; Souza AM; Melchior E; Gouveia EG; Carvalho D
Lepr Rev; 1997 Sep; 68(3):212-7. PubMed ID: 9364821
[TBL] [Abstract][Full Text] [Related]
55. Hepatic and haematological adverse reactions associated with the use of multidrug therapy in leprosy--a five year retrospective study.
Kaluarachchi SI; Fernandopulle BM; Gunawardane BP
Indian J Lepr; 2001; 73(2):121-9. PubMed ID: 11579648
[TBL] [Abstract][Full Text] [Related]
56. Effectiveness of MDT in multibacillary leprosy.
Jesudasan K; Vijayakumaran P; Manimozhi N; Rao PS; Samuel P
Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):128-32. PubMed ID: 8690970
[TBL] [Abstract][Full Text] [Related]
57. Prospective study on the relationship between intensive bactericidal therapy and leprosy reactions.
Groenen G; Janssens L; Kayembe T; Nollet E; Coussens L; Pattyn SR
Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):236-44. PubMed ID: 3722962
[TBL] [Abstract][Full Text] [Related]
58. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy.
Jing Z; Zhang R; Zhou D; Chen J
Lepr Rev; 2009 Jun; 80(2):170-6. PubMed ID: 19743621
[TBL] [Abstract][Full Text] [Related]
59. Clofazimine: new products. Major antileprous drug.
Prescrire Int; 1999 Apr; 8(40):44-6. PubMed ID: 10848059
[TBL] [Abstract][Full Text] [Related]
60. [Guideline for the treatment of Hansen's disease in Japan (Second edition)].
Goto M; Nogami R; Hatano K; Okano Y; Ishii N; Gidoh M; Ishida Y; Ozaki M;
Nihon Hansenbyo Gakkai Zasshi; 2006 Sep; 75(3):191-226. PubMed ID: 17037376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
